Atossa Therapeutics (ATOS) Other Non Operating Income (2014 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Other Non Operating Income of -$28000.0 for Q1 2026, down 16.67% year-over-year from -$33600.0 in Q1 2025, and down 144.44% quarter-over-quarter from $63000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Other Non Operating Income (2014 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Other Non Operating Income for 11 consecutive years, with -$28000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 16.67% year-over-year to -$28000.0; the TTM figure through Mar 2026 stood at -$4000.0 (down 101.61% YoY), while the FY2024 annual figure was $235000.0, up 435.71% from the prior year.
- Other Non Operating Income fell to -$28000.0 in Q1 2026 per ATOS's latest filing, from $63000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $425000.0 in Q4 2024 and bottomed at -$136000.0 in Q3 2024.
- Historically, Other Non Operating Income has averaged $21750.0 across 5 years, with a median of -$28000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 471.43% — and 2024, when it soared 1365.52%.
- Atossa Therapeutics' Other Non Operating Income stood at $337000.0 in 2022, then tumbled by 91.39% to $29000.0 in 2023, then jumped by 1365.52% to $425000.0 in 2024, then plunged by 85.18% to $63000.0 in 2025, then tumbled by 144.44% to -$28000.0 in 2026.
- Business Quant data shows ATOS's Other Non Operating Income at -$28000.0 in Q1 2026, $63000.0 in Q4 2025, and -$11000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24,000.00 |
| Mar 31, 2026 | -28,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Sep 30, 2024 | -136,000.00 |
| Jun 30, 2024 | -17,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | 29,000.00 |
| Sep 30, 2023 | -35,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | -33,000.00 |
| Dec 31, 2022 | 337,000.00 |
| Jun 30, 2022 | -88,000.00 |
| Mar 31, 2022 | -40,000.00 |
| Dec 31, 2021 | -476,000.00 |
| Sep 30, 2021 | -39,000.00 |
| Jun 30, 2021 | -35,000.00 |